EP2445487A2 — Controlled release formulations
Assigned to Egalet Ltd · Expires 2012-05-02 · 14y expired
What this patent protects
The present invention relates to the field of controlled release formulations, and in particular to formulations useful for once daily administration. More particular, the present invention relates to compositions, which are formulated for continued administration to an individua…
USPTO Abstract
The present invention relates to the field of controlled release formulations, and in particular to formulations useful for once daily administration. More particular, the present invention relates to compositions, which are formulated for continued administration to an individual in need thereof within the range of 20 to 28 hours interval between individual administrations.
Drugs covered by this patent
- Risperdal (risperidone) · Johnson & Johnson (Janssen)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.